Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Atar

Showing results (11-20 of 405) with videos related to

Pageof 41
Sort By:
Fundamental & Clinical Pharmacology|February 25, 2009
Interpreting clinical trials: the 'beautiful' caseStefan Agewall, Dan Atar
European Heart Journal|October 23, 2015
Morphine in myocardial infarction: balancing on the tight ropeDan Atar, Stefan Agewall
Scandinavian Cardiovascular Journal. Supplement|October 17, 2012
Pharmacological conversion of recent-onset atrial fibrillation: a systematic reviewMagnus Heldal, Dan Atar
European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
End of story? Studies on prevention of reperfusion injury encounter perpetual defeatsDan Atar, Stefan Agewall
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 15, 2015
Non-vitamin K oral anticoagulants in 'valvular' atrial fibrillation: a call for actionJan Steffel, Dan Atar
The American Journal of Cardiology|May 2, 2009
In ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention, admission cardiac troponin T and peak cardiac troponin T values differ in their prognostic propertiesJonas Hallén, Dan Atar
Circulation. Cardiovascular Quality and Outcomes|May 16, 2013
Prasugrel: the real-life perspectiveVictor Serebruany, Dan Atar
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 13, 2021
Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?Andrea Rubboli, Dan Atar
Cardiology|January 6, 2026
Subclinical Atherosclerotic Coronary Artery Disease: Considerations on a New Modifier of Cardiovascular RiskAndrea Rubboli, Dan Atar
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
Cost-effectiveness of antiplatelet drugs after percutaneous coronary interventionTorbjørn Wisløff, Dan Atar
Pageof 41

Showing results (11-20 of 405) with videos related to

Sort By:
Pageof 41
Fundamental & Clinical Pharmacology|February 25, 2009
Interpreting clinical trials: the 'beautiful' caseStefan Agewall, Dan Atar
European Heart Journal|October 23, 2015
Morphine in myocardial infarction: balancing on the tight ropeDan Atar, Stefan Agewall
Scandinavian Cardiovascular Journal. Supplement|October 17, 2012
Pharmacological conversion of recent-onset atrial fibrillation: a systematic reviewMagnus Heldal, Dan Atar
European Heart Journal. Cardiovascular Pharmacotherapy|August 18, 2016
End of story? Studies on prevention of reperfusion injury encounter perpetual defeatsDan Atar, Stefan Agewall
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|October 15, 2015
Non-vitamin K oral anticoagulants in 'valvular' atrial fibrillation: a call for actionJan Steffel, Dan Atar
The American Journal of Cardiology|May 2, 2009
In ST-Elevation myocardial infarction patients receiving primary percutaneous coronary intervention, admission cardiac troponin T and peak cardiac troponin T values differ in their prognostic propertiesJonas Hallén, Dan Atar
Circulation. Cardiovascular Quality and Outcomes|May 16, 2013
Prasugrel: the real-life perspectiveVictor Serebruany, Dan Atar
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|July 13, 2021
Modulating the Intensity of Oral Anticoagulation Therapy with Direct Oral Anticoagulants: Feasible or Not?Andrea Rubboli, Dan Atar
Cardiology|January 6, 2026
Subclinical Atherosclerotic Coronary Artery Disease: Considerations on a New Modifier of Cardiovascular RiskAndrea Rubboli, Dan Atar
European Heart Journal. Quality of Care & Clinical Outcomes|February 24, 2018
Cost-effectiveness of antiplatelet drugs after percutaneous coronary interventionTorbjørn Wisløff, Dan Atar
Pageof 41